Age & purpose verification
PeptideSeed supplies research compounds for in-vitro laboratory use only. By entering this site you confirm:
Research use only. Not for human or veterinary consumption. Full terms of supply
BPC-157 and TB-500 are the two most-requested regenerative sequences in the catalogue. How they differ in origin, length, solubility and handling.
BPC-157 is a synthetic 15-residue sequence derived from a partial sequence of Body Protection Compound, a peptide originally isolated from human gastric juice. TB-500 is the synthetic acetylated form of the active region of Thymosin Beta-4, a 43-residue actin-sequestering peptide found broadly across mammalian tissue.
Neither shares a sequence, a biochemical target, or a discovery history with the other. Their frequent pairing in bench work is a matter of complementary study interest rather than structural relationship.
BPC-157 is 15 residues at 1419.53 g/mol. TB-500 is 43 residues at 4963.44 g/mol - roughly three and a half times the mass. That difference in chain length is the single biggest driver of the cost and handling differences between the two.
Synthesis cost scales with chain length because each additional residue is another coupling step, and longer chains require more aggressive purification to reach the same purity specification. TB-500's higher per-milligram cost traces directly to this.
Both sequences are readily soluble in sterile or bacteriostatic water, but they do not dissolve at the same rate. BPC-157 clears from its lyophilized cake quickly with gentle swirling. TB-500, being both longer and higher in molecular weight, takes noticeably longer to fully dissolve.
The correct response to slow TB-500 dissolution is patience, not agitation. Vortexing a peptide vial to force faster dissolution shears longer sequences, and TB-500's length makes it more susceptible to that damage than the shorter BPC-157.
BPC-157 carries no cysteine and forms no disulfide bridges, which contributes to its being one of the more stable sequences in the catalogue in aqueous solution across extended incubation. TB-500 carries a single methionine, which is modestly oxidation-sensitive, so vials should stay sealed and desiccated until the point of use.
Both are rated for the same thirty-day reconstituted hold time at 2-8 C under standard catalogue guidance, but TB-500's oxidation sensitivity makes prompt, careful sealing after each access more important.
Because these two sequences are the pair most frequently ordered together, PeptideSeed offers them as a co-lyophilized Wolverine Blend at a 1:1 mass ratio in a single vial, removing one reconstitution step and one source of measurement error relative to preparing each separately.
Reconstituting the blend requires patience for the same reason as reconstituting TB-500 alone: the slower-dissolving component should be given time to fully clear before the vial is drawn, or the ratio actually delivered in an aliquot will not match the stated 1:1 composition.
The two are commonly run side by side in comparative bench work precisely because they are mechanistically unrelated - BPC-157's stability and TB-500's actin-binding profile give researchers two independent variables to compare rather than two readings of the same underlying property.
Anyone choosing between the standalone vials and the Wolverine Blend should base the decision on whether both are actually needed for the protocol at hand, since the blend format is a convenience rather than a different material.
This guide is general laboratory reference material relating to the handling of research compounds. It is not medical, veterinary or clinical guidance, and it does not describe or imply any use in humans or animals. All PeptideSeed material is supplied for in-vitro laboratory research only — see the terms of supply.